Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: A focus on pentacycloundecane derivatives

被引:183
作者
Geldenhuys, WJ
Malan, SF
Bloomquist, JR
Marchand, AP
Van der Schyf, CJ [1 ]
机构
[1] Texas Tech Univ, Sch Pharm, Dept Pharmaceut Sci, Hlth Sci Ctr, Amarillo, TX 79106 USA
[2] Virginia Polytech Inst & State Univ, Dept Entomol, Neurotoxicol Lab, Blacksburg, VA 24061 USA
[3] Univ N Texas, Dept Chem, Denton, TX 76203 USA
[4] N W Univ, Sch Pharm, ZA-2520 Potchefstroom, South Africa
关键词
adamantylamines; amantadine; bird-cage compounds; diamondoids; homocubylamines; memantine; NGPI-01; pentacycloudecylamines; polycyclic cage; triquinanes; trishomocubylamines;
D O I
10.1002/med.20013
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The chemistry of organic polycyclic cage compounds has intrigued medicinal chemists for over 50 years, yet little is published about their pharmacological profiles. Polycyclic cage compounds have important pharmaceutical applications, ranging from the symptomatic and proposed curative treatment of neurodegenerative diseases such as Parkinson's and Alzheimer's disease (e.g., amantadine and memantine), to use as anti-viral agents against influenza and the immunodeficiency virus (HIV). The polycyclic cage appears to be a useful scaffold to yield drugs with a wide scope of applications, and can be used also to modify and improve the pharmacokinetic and pharmacodynamic properties of drugs in current use. This review attempts to summarize the pharmacological profiles of polycyclic cage compounds with an emphasis on the lesser known pentacycloundecanes, homocubanes, and trishomocubanes. (C) 2004 Wiley Periodicals, Inc.
引用
收藏
页码:21 / 48
页数:28
相关论文
共 110 条
  • [1] Synthesis and SAR of adatanserin:: Novel adamantyl aryl- and heteroarylpiperazines with dual serotonin 5-HT1A and 5-HT2 activity as potential anxiolytic and antidepressant agents
    Abou-Gharbia, MA
    Childers, WE
    Fletcher, H
    McGaughey, G
    Patel, U
    Webb, MB
    Yardley, J
    Andree, T
    Boast, C
    Kucharik, RJ
    Marquis, K
    Morris, H
    Scerni, R
    Moyer, JA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (25) : 5077 - 5094
  • [3] BOEYENS JCA, 1994, S AFR J CHEM-S-AFR T, V47, P72
  • [4] DIFFERENT BINDING AFFINITIES OF NMDA RECEPTOR-CHANNEL BLOCKERS IN VARIOUS BRAIN-REGIONS - INDICATION OF NMDA RECEPTOR HETEROGENEITY
    BRESINK, I
    DANYSZ, W
    PARSONS, CG
    MUTSCHLER, E
    [J]. NEUROPHARMACOLOGY, 1995, 34 (05) : 533 - 540
  • [5] BROOKES KB, 1992, S AFR J CHEM-S-AFR T, V45, P8
  • [6] NMDA ANTAGONISTS PARTIALLY PROTECT AGAINST MPTP INDUCED NEUROTOXICITY IN MICE
    BROUILLET, E
    BEAL, MF
    [J]. NEUROREPORT, 1993, 4 (04) : 387 - 390
  • [7] CARTER AJ, 1994, J PHARMACOL EXP THER, V269, P573
  • [8] Neuroprotection in the MPTP parkinsonian C57BL/6 mouse model by a compound isolated from tobacco
    Castagnoli, KP
    Steyn, SJ
    Petzer, JP
    Van der Schyf, CJ
    Castagnoli, N
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2001, 14 (05) : 523 - 527
  • [9] ADAMANTANE AND PROTOADAMANTANEALKANAMINES AS POTENTIAL ANTI-PARKINSON AGENTS .10.
    CHAKRABARTI, JK
    HOTTEN, TM
    SUTTON, S
    TUPPER, DE
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1976, 19 (07) : 967 - 969
  • [10] COETZEE WA, Patent No. 0312245